Technology

 

HµRELflow™

 

 

The metabolic competency of HμREL^®'s patented flow-based (i.e., perfusion-based) biochips and instrumentation enables parent compound clearance and metabolite generation significantly greater than that afforded by hepatocytes cultured under static conditions, when presented to compounds that invoke the broad range of Phase I and Phase II metabolic enzymes.  HμREL^®'s flow-based metabolic competency has been shown stable for 14 days and longer.